ArticleTheranostics2020
Depletion of the diabetic gut microbiota resistance enhances stem cells therapy in type 1 diabetes mellitus.
Article in Theranostics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 2 syntheses or guidelines pooled it, 61 citations in OpenAlex.
- Safety and efficacy of fecal microbiota transplantation for autoimmune diseases and autoinflammatory diseases: A systematic review and meta-analysis.Frontiers in immunology · 2022Pooled it
- Enterochromaffin Cells: Sentinels to Gut Microbiota in Hyperalgesia?Frontiers in cellular and infection microbiology · 2021Pooled it
- Diet and Lipidomics Mediated Regulation of Mesenchymal Stem Cell Function: Diet, Omics and Stem Cell Connection.Biomolecules · 2026Review
- Childhood type 1 diabetes mellitus and gut microbiota: from microbiome characteristics to prevention and treatment strategies.Frontiers in cellular and infection microbiology · 2026Review
- Nicotine exacerbates MASH via inducing intestinal dysbiosis and barrier dysfunction.Communications biology · 2025Article
- Gut microbiota development across the lifespan: Disease links and health-promoting interventions.Journal of internal medicine · 2025Review
- Exploring the role of gut microbiota modulation in the long-term therapeutic benefits of early MSC transplantation in MRL/lpr mice.Cellular & molecular biology letters · 2025Article
- Unleashing the Potential: Exploring the Application and Mechanism of Mesenchymal Stem Cells in Autoimmune Diseases.Stem cells international · 2025Review
- Fecal microbiota transplantation from gestational diabetes mellitus patients induces glucose intolerance and subclinical inflammation in mice.Frontiers in microbiology · 2025Article
- Research Progress in the Relationship between Intestinal Flora and Diabetes Mellitus.Endocrine, metabolic & immune disorders drug targets · 2025Review
- Gut microbiome shifts in people with type 1 diabetes are associated with glycaemic control: an INNODIA study.Diabetologia · 2024Article
- Human umbilical cord-derived mesenchymal stem cells alleviate oxidative stress-induced islet impairment via the Nrf2/HO-1 axis.Journal of molecular cell biology · 2023Article
- Nd:YAG-photobiomodulation enhanced ADSCs multilineage differentiation and immunomodulation potentials.Lasers in medical science · 2023Article
- Gut Microbiota and Critical Metabolites: Potential Target in Preventing Gestational Diabetes Mellitus?Microorganisms · 2023Review
- Construction of model animals to explore intestinal microbiome for detection of breast cancer.PloS one · 2023Article
- Exploring a novel therapeutic strategy: the interplay between gut microbiota and high-fat diet in the pathogenesis of metabolic disorders.Frontiers in nutrition · 2023Review
- hUCMSCs carrying exenatide prevent T1DM by improving intestinal microflora composition and islet tissue damage repair.Molecular medicine (Cambridge, Mass.) · 2022Article
- Human umbilical cord-derived mesenchymal stem cells ameliorate experimental colitis by normalizing the gut microbiota.Stem cell research & therapy · 2022Article
- Adipose-derived stem cells postpone the progression of Sjögren's syndrome by upregulating the Hippo signaling pathway.Experimental and therapeutic medicine · 2022Article
- Comparison of therapeutic effects of mesenchymal stem cells from umbilical cord and bone marrow in the treatment of type 1 diabetes.Stem cell research & therapy · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Microbiome, considered as the "second genome" of the host, is altered in type 1 diabetes mellitus (T1DM) patients to a state of dysbiosis. Mesenchymal stem cell (MSC) transplantation is a promising treatment for T1DM but is limited by several factors in the diabetic host. In this study, we tested the hypothesis that dysbiotic gut microbiota may limit MSC therapy, and modulating gut microbiota may help to improve the effects of MSC transplantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.